Post-Transplant Cyclophosphamide after Matched Sibling and Unrelated Donor Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Myeloid Leukemia

Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Kris M. Mahadeo(Duke University), Elizabeth J. Shpall(Scripps MD Anderson Cancer Center), Uday Popat(The University of Texas MD Anderson Cancer Center), Dristhi Ragoonanan(The University of Texas MD Anderson Cancer Center), Shaikha Alqahtani(Duke University), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center)
International Journal of Molecular Sciences
August 6, 2022
10.3390/ijms23158748
Cited by 6

Related Papers

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial
|Nature Medicine|2024|452
Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
|Blood|2004|422
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
|Nature Reviews Clinical Oncology|2018|237
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
|Nature Medicine|2023|226
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
|Blood|2021|213